Do both provoked and unprovoked Deep Vein Thrombosis (DVT) contribute to the CHA2DS2-VASc score?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Guidelines

Neither provoked nor unprovoked Deep Vein Thrombosis (DVT) contributes points toward the CHA2DS2-VASc score. The CHA2DS2-VASc score is designed to assess stroke risk in patients with atrial fibrillation and includes points for Congestive heart failure, Hypertension, Age (≥75 years counts as 2 points, 65-74 years as 1 point), Diabetes, prior Stroke/TIA/thromboembolism (2 points), Vascular disease, and Sex category (female) 1. Deep vein thrombosis, whether provoked or unprovoked, is not included in this scoring system. If you're assessing venous thromboembolism risk, different scoring systems such as the Wells score or IMPROVE VTE risk assessment would be more appropriate. These systems do consider previous DVT history as a risk factor, but they are distinct from the CHAD2VASC score used for atrial fibrillation patients. Some studies discuss the categorization of patients as having provoked or unprovoked venous thromboembolism, but this is not relevant to the CHA2DS2-VASc score 2. The most recent and highest quality study on the topic of anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 does not mention DVT as a component of the score 3.

Some key points to consider when assessing stroke risk in patients with atrial fibrillation include:

  • The CHA2DS2-VASc score is a widely used and recommended tool for assessing stroke risk in patients with atrial fibrillation 1
  • The score includes points for several clinical factors, but does not include DVT
  • Different scoring systems, such as the Wells score or IMPROVE VTE risk assessment, are used to assess venous thromboembolism risk and do consider previous DVT history as a risk factor.

From the Research

Contribution to CHA2DS2-VASc Score

  • The CHA2DS2-VASc score is used to estimate the risk of stroke in patients with atrial fibrillation, not directly related to Deep Vein Thrombosis (DVT) [ 4, 5, 6, 7, 8 ].
  • However, studies have shown that patients with unprovoked VTE have a higher risk of arterial cardiovascular events than patients with provoked VTE [ 4, 5 ].
  • The risk of recurrent VTE is higher in patients with unprovoked VTE than in those with provoked VTE [ 6, 7 ].
  • The CHA2DS2-VASc score does not directly account for the distinction between provoked and unprovoked DVT [ 4, 5, 6, 7, 8 ].

Provoked and Unprovoked DVT

  • Provoked DVT is associated with a higher risk of major arterial events, particularly in patients with cancer [ 5 ].
  • Unprovoked DVT is associated with a higher risk of recurrent VTE [ 6, 7 ].
  • The distinction between provoked and unprovoked DVT is important for determining the risk of recurrent VTE and the optimal duration of anticoagulation therapy [ 6, 7, 8 ].

Relevance to CHA2DS2-VASc Score

  • There is no direct evidence that both provoked and unprovoked DVT contribute to the CHA2DS2-VASc score [ 4, 5, 6, 7, 8 ].
  • The CHA2DS2-VASc score is primarily used to estimate the risk of stroke in patients with atrial fibrillation, and its application to DVT is not well established [ 4, 5, 6, 7, 8 ].

References

Research

Overview of venous thromboembolism.

The American journal of managed care, 2017

Related Questions

For a patient with a provoked deep vein thrombosis due to oral‑contraceptive (OCP) use, what anticoagulation duration is recommended by the American Society of Hematology (ASH) and the American College of Chest Physicians (ACCP), when should extended or indefinite therapy be considered, and how should follow‑up monitoring for efficacy and safety be planned?
Is a hypercoagulable workup necessary for all patients with unprovoked Pulmonary Embolism (PE)?
What is the typical pain pattern associated with Deep Vein Thrombosis (DVT)?
What are the implications of right ankle swelling and bulging veins in the lower leg while on Eliquis (apixaban) for pulmonary embolism (PE)?
In a patient with a first unprovoked deep vein thrombosis, no personal or family history of thrombophilia, currently on warfarin for three months with a therapeutic INR of 2.5, what is the appropriate management?
Are there any contraindications to Symbicort (budesonide and formoterol) in pregnancy?
What is the recommended dose of ibuprofen (nonsteroidal anti-inflammatory drug, NSAID) for a 90-year-old patient with hyperthermia (fever)?
Is a lumbar (lower back) compression fracture with 50% height loss considered a stable fracture?
What is the relationship between ejaculation, sexual intercourse, and masturbation on prostate health, and are there optimal frequencies to prevent issues such as prostatitis or benign prostatic hyperplasia (BPH)?
At what Glomerular Filtration Rate (GFR) should a patient discontinue lithium (lithium carbonate) therapy due to Impaired Renal Function?
Is it safe to prescribe high-dose lithium and aripiprazole (Abilify)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.